Clinical Trial Update: Camrelizumab Combined With Apatinib for Recurrent Resistant GTN [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab with apatinib for recurrent resistant gestational trophoblastic disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gestational Trophoblastic Disease

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Gestational Trophoblastic Disease | Phase 2 | Status: COMPLETED